The BuMA sirolimus-eluting stent (SES) proved noninferior to the Excel SES, according to the results of the PANDA III trial, presented Oct. 14 at TCT 2015.

Led by Bo Xu, MBBS, the study sought to evaluate the clinical benefits of the BuMA SES, compared to the Excel SES, at one-year follow-up. Researchers examined the effect of the rate of drug elution and polymer absorption on the clinical outcomes of the two bioresorbable polymer-based drug-eluting stents. Inclusion criteria for the patient population were those with symptomatic coronary artery disease, silent ischemia, or acute coronary syndrome, and who qualified for percutaneous coronary intervention. The primary endpoint was one-year target lesion failure and a composite of cardiac death, target vessel myocardial infarction (MI) or ischemia driven target lesion revascularization.

The results of the study showed that the BuMA SES was noninferior to the Excel SES, with no significant differences in the acute success rates, target lesion failure components, or patient-oriented composite all-cause death, all MI or revascularization.

According to Xu, “the BuMA SES was also associated with a lower incidence of stent thrombosis compared to the Excel SES, which is consistent with previous findings of enhanced strut coverage with this device. Longer follow up is needed to further understand the long-term effects of this emerging stent technology.”

Keywords: Transcatheter Cardiovascular Therapeutics, Drug-Eluting Stents, Kinetics, Polymers, Sirolimus, Stents, Acute Coronary Syndrome, Coronary Artery Disease, Coronary Disease, Myocardial Infarction, Percutaneous Coronary Intervention, Polymers, Thrombosis

< Back to Listings